3 Cash-Producing Stocks We Keep Off Our Radar
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Not all companies are created equal, and StockStory is here to surface the ones with real upside. Keeping that in mind, here are three cash-producing companies to steer clear of and a few better alternatives.
Caleres (CAL)
Trailing 12-Month Free Cash Flow Margin: 1.4%
The owner of Dr. Scholl's, Caleres (NYSE:CAL) is a footwear company offering a range of styles.
Why Is CAL Risky?
- Annual revenue growth of 5.4% over the last five years was below our standards for the consumer discretionary sector
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
- 8× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly
Caleres’s stock price of $13.09 implies a valuation ratio of 8.6x forward P/E. Read our free research report to see why you should think twice about including CAL in your portfolio.
Smith & Wesson (SWBI)
Trailing 12-Month Free Cash Flow Margin: 11.2%
With a history dating back to 1852, Smith & Wesson (NASDAQ:SWBI) is a firearms manufacturer known for its handguns and rifles.
Why Should You Sell SWBI?
- Sales tumbled by 12.2% annually over the last five years, showing consumer trends are working against its favor
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
- Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value
Smith & Wesson is trading at $15.28 per share, or 48.2x forward P/E. Check out our free in-depth research report to learn more about why SWBI doesn’t pass our bar.
Haemonetics (HAE)
Trailing 12-Month Free Cash Flow Margin: 23.4%
With roots dating back to 1971 and a mission to improve blood-related healthcare, Haemonetics (NYSE:HAE) provides specialized medical devices and software for blood collection, processing, and management across plasma centers, blood banks, and hospitals.
Why Are We Wary of HAE?
- Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
- Smaller revenue base of $1.32 billion means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- ROIC of 6.6% reflects management’s challenges in identifying attractive investment opportunities
At $59.71 per share, Haemonetics trades at 11.4x forward P/E. If you’re considering HAE for your portfolio, see our FREE research report to learn more.
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
